MIGENIX and Schering-Plough Sign Agreement for MX-3253 Hepatitis C Drug Development and License OptionMIGENIX Inc. • July 13th, 2005 • Pharmaceutical preparations
Vancouver, BC, CANADA & San Diego, CA, USA – July 13, 2005– MIGENIX Inc. (TSX: MGI; OTC: MGIFF), a clinical-stage developer of drugs for infectious and degenerative diseases, has completed a Material Transfer and License Option Agreement (“Agreement”) with Schering-Plough Corporation (NYSE: SGP) of Kenilworth, N.J., related to celgosivir (MX-3253), MIGENIX’s first-in-class compound in Phase II clinical development for the treatment of chronic Hepatitis C Virus (HCV) infections.
